Member Info for share12345

Much has been written about the growth in the Indian economy and the directors believe that the prospects for the Facility have continued to strengthen. In addition to the general economic climate, there are specific initiatives that are expected to have a beneficial impact on the Company. In particular, the pipeline that runs across the mouth of Karanja creek and which currently limits the draft capacity of vessels using the port, is proposed to be moved by the Government.

As at the 31st March, the Company had cash and undrawn banking facilities of £22.4 million. The Company continues to manage its resources in line with the timetable to operation. As a result of the date of revenue receipts being later than anticipated, the Company has, pending receipt of customs' clearance,

this could double from here next news whin in two weeks

could do with some buys this then will take off.. good start

nice20k buy

should be 3.5 p plus more news on the way great rns

big news

n addition, the Board is excited by the value creation opportunities that should be possible from the certainty of an additional 20 years of cash flows.

musy see this rerate up now

Major shareholders – expected holdings post fundraise Shareholder Number of Ordinary Shares Share Capital Miton Group 14,764,502 11.06% João Andrade 8,388,333 6.28% Lopes Gil 8,316,667 6.23% Dominus Investments 4,311,386 3.23% Joseph Ferreira 3,836,292 2.87% Luis Gil 3,776,000 2.82% Graham Hine 3,178,698 2.38%

could do with some buys

about to go blue

blue within 1 hour

may get to 3p

Human Application Licence In February this year the UK Human Tissue Authority further awarded WideCells Ltd a Human Application Licence. This licence permits the company to import, export, process, store and distribute for treatment, umbilical cord blood and umbilical cord tissue from the UK and Europe in its Manchester facilities. The licence now enables the company, under the BabyCells brand name, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe. BabyCells will be charged at a cost of circa £2,000 to £2,500 per sample for one year's storage (including collection and processing), with recurring storage revenues of £50-£75 per annum thereafter and alternative multi-year pre-paid storage plans. Clients of BabyCells will be offered one year's stem cell insurance cover, provided by CellPlan, reflecting the synergous nature of the two divisions. To support roll-out, WideCells will actively look for agents, initially focussing on Europe, to promote its stem cell storage services, providing them with services including marketing, training, custom designed collection devices, software maintenance and technical suppor

back to 2.1 need top get past this point

Asia-Pacific In March this year WideCells announced a landmark deal with Cryoviva Group, an established cord blood storage facility with operations in Thailand, Singapore and India, to sell CellPlan in Asia. Cryoviva has c.250,000 inspected samples stored to-date which represents almost 9% of all samples stored worldwide, with forecasts to store c.25,000 new samples every year. CellPlan will be launched to Cryoviva customers on a phased basis, commencing in H2 2018, providing staged revenue increases. This provides WideCells with exposure to another high growth region, with the Asia- Pacific stem cell market expected to grow at a CAGR of 14.6% from 2017 to 2025

Conclusion WideCells has performed well since IPO by building up three divisions with attractive commercial propositions. While there have been some delays around the timing of product launches, the company now has numerous revenue streams with huge potential for growth, long-term recurring income and deals with respected partners to advance its scalable global growth strategy. In addition, the current fundraising (assuming completion) positions the company well to fulfill its business plan. We also note that directors’ interests are closely aligned with shareholders, with them having a combined 25.8% share holding. Overall, recognising the early stage nature of the business, but considering the very low valuation should indicative forecasts be met, we initiate coverage of WideCells with a stance of Conviction Buy and price target of 12p, being just under 5 times 2020

this should now fly, rerate

good read.